S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:CASI

CASI Pharmaceuticals Competitors

$2.18
-0.21 (-8.79 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.10
Now: $2.18
$2.42
50-Day Range
$2.39
MA: $3.11
$3.63
52-Week Range
$1.15
Now: $2.18
$3.90
Volume353,279 shs
Average Volume503,281 shs
Market Capitalization$270.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41

Competitors

CASI Pharmaceuticals (NASDAQ:CASI) Vs. MESO, CRTX, ADVM, INBX, AERI, and PASG

Should you be buying CASI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to CASI Pharmaceuticals, including Mesoblast (MESO), Cortexyme (CRTX), Adverum Biotechnologies (ADVM), Inhibrx (INBX), Aerie Pharmaceuticals (AERI), and Passage Bio (PASG).

Mesoblast (NASDAQ:MESO) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Mesoblast and CASI Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.54$-77,940,000.00($0.74)-12.41
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19

CASI Pharmaceuticals has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Mesoblast and CASI Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
CASI Pharmaceuticals00203.00

Mesoblast presently has a consensus price target of $14.55, indicating a potential upside of 58.50%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 94.95%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Mesoblast.

Profitability

This table compares Mesoblast and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
CASI Pharmaceuticals-402.87%-60.96%-42.48%

Insider and Institutional Ownership

2.8% of Mesoblast shares are owned by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Mesoblast has a beta of 3.71, indicating that its share price is 271% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

CASI Pharmaceuticals beats Mesoblast on 9 of the 13 factors compared between the two stocks.

CASI Pharmaceuticals (NASDAQ:CASI) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares CASI Pharmaceuticals and Cortexyme's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme has lower revenue, but higher earnings than CASI Pharmaceuticals. Cortexyme is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CASI Pharmaceuticals and Cortexyme, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CASI Pharmaceuticals00203.00
Cortexyme21402.29

CASI Pharmaceuticals currently has a consensus price target of $4.25, suggesting a potential upside of 94.95%. Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than Cortexyme.

Insider and Institutional Ownership

32.0% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 24.8% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares CASI Pharmaceuticals and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CASI Pharmaceuticals-402.87%-60.96%-42.48%
CortexymeN/A-37.78%-35.24%

Volatility and Risk

CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Summary

Cortexyme beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Adverum Biotechnologies and CASI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19

CASI Pharmaceuticals has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Adverum Biotechnologies and CASI Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
CASI Pharmaceuticals00203.00

Adverum Biotechnologies currently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. CASI Pharmaceuticals has a consensus target price of $4.25, suggesting a potential upside of 94.95%. Given Adverum Biotechnologies' higher possible upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than CASI Pharmaceuticals.

Profitability

This table compares Adverum Biotechnologies and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
CASI Pharmaceuticals-402.87%-60.96%-42.48%

Institutional & Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Adverum Biotechnologies has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

CASI Pharmaceuticals (NASDAQ:CASI) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

32.0% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.6% of Inhibrx shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CASI Pharmaceuticals and Inhibrx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CASI Pharmaceuticals00203.00
Inhibrx00403.00

CASI Pharmaceuticals presently has a consensus target price of $4.25, suggesting a potential upside of 94.95%. Inhibrx has a consensus target price of $34.6667, suggesting a potential upside of 30.52%. Given CASI Pharmaceuticals' higher probable upside, research analysts plainly believe CASI Pharmaceuticals is more favorable than Inhibrx.

Valuation and Earnings

This table compares CASI Pharmaceuticals and Inhibrx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19
InhibrxN/AN/AN/AN/AN/A

Inhibrx has lower revenue, but higher earnings than CASI Pharmaceuticals.

Profitability

This table compares CASI Pharmaceuticals and Inhibrx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CASI Pharmaceuticals-402.87%-60.96%-42.48%
InhibrxN/AN/AN/A

Summary

Inhibrx beats CASI Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

CASI Pharmaceuticals (NASDAQ:CASI) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CASI Pharmaceuticals and Aerie Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CASI Pharmaceuticals00203.00
Aerie Pharmaceuticals11902.73

CASI Pharmaceuticals presently has a consensus target price of $4.25, indicating a potential upside of 94.95%. Aerie Pharmaceuticals has a consensus target price of $25.50, indicating a potential upside of 32.47%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Aerie Pharmaceuticals.

Valuation and Earnings

This table compares CASI Pharmaceuticals and Aerie Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66

CASI Pharmaceuticals has higher earnings, but lower revenue than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.0% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are held by institutional investors. 24.8% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Aerie Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

CASI Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares CASI Pharmaceuticals and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CASI Pharmaceuticals-402.87%-60.96%-42.48%
Aerie Pharmaceuticals-231.05%-135.57%-37.23%

Passage Bio (NASDAQ:PASG) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Passage Bio and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Passage BioN/AN/AN/A
CASI Pharmaceuticals-402.87%-60.96%-42.48%

Earnings and Valuation

This table compares Passage Bio and CASI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/AN/AN/AN/A
CASI Pharmaceuticals$4.13 million65.42$-46,030,000.00($0.42)-5.19

Passage Bio has higher earnings, but lower revenue than CASI Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Passage Bio and CASI Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Passage Bio02602.75
CASI Pharmaceuticals00203.00

Passage Bio presently has a consensus price target of $25.5297, indicating a potential upside of 31.39%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 94.95%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Passage Bio.

Summary

Passage Bio beats CASI Pharmaceuticals on 5 of the 9 factors compared between the two stocks.


CASI Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.